Last updated: February 13, 2026
Overview
NDC 70677-1076 corresponds to Rucaparib, marketed as Rubraca. It is an oral PARP inhibitor approved by the FDA for the maintenance treatment of recurrent ovarian cancer and certain BRCA-mutated prostate cancers. The drug has gained market traction primarily within oncology.
Market Size and Trends
-
Global Oncology Drugs Market: Valued at approximately $160 billion in 2022, with targeted therapies comprising roughly 40%. The demand for PARP inhibitors like Rucaparib has grown notably due to improvements in biomarker-driven treatments.
-
U.S. Market Share: Rucaparib's sales reached $300 million in 2022, representing about 6.6% of the targeted ovarian cancer market segment [1]. Its primary competitors include Olaparib (Lynparza) and Niraparib (Zejula).
-
Patient Population: Estimated at 22,000 new ovarian cancer cases annually in the U.S., with a subset having BRCA mutations. Prostate cancer with homologous recombination deficiency (HRD) is an emerging indication, expanding the potential patient base.
-
Pricing Trends: Rucaparib's wholesale acquisition cost (WAC) is approximately $11,000 per 30-day supply. Annual treatment exceeds $132,000, aligning with other PARP inhibitors [2].
Competitive Landscape
| Drug |
Indication |
2022 Sales |
Market Share |
Price per Month |
Notes |
| Rucaparib (Rubraca) |
Ovarian and prostate cancers |
~$300M |
6.6% |
$11,000 |
First PARP inhibitor approved for prostate |
| Olaparib (Lynparza) |
Ovarian, breast, pancreatic, prostate |
>$2B |
44% |
$13,300 |
Largest market share, widely used |
| Niraparib (Zejula) |
Ovarian cancer |
~$600M |
13.3% |
$10,900 |
Predominantly ovarian indication |
Regulatory and Pipeline Updates
-
Expansion Opportunities: Approved for maintenance in first-line ovarian cancer; further trials for prostate, breast, and pancreatic cancers underway.
-
Patent and Exclusivity: U.S. patent protection until 2031; potential for biosimilars post-expiry could impact prices.
-
Pricing Pressure: Cost-effectiveness analyses have nuanced effects on reimbursement policies, especially with increasing competition and biosimilars.
Price Projections (2023-2028)
| Year |
Estimated Average Price per Month |
Key Factors Influencing Price |
| 2023 |
$11,000 |
Stable patent protections, high demand |
| 2024 |
$10,900 |
Emerging biosimilar competition, pricing negotiations |
| 2025 |
$10,500 |
Further biosimilar entries, payer discounts |
| 2026 |
$10,200 |
Increased biosimilar market penetration |
| 2027 |
$9,800 |
Cost pressure, demand stabilization |
| 2028 |
$9,500 |
Biosimilar availability, patent expiry likely |
Market Dynamics
-
Pricing trends indicate gradual decrease driven by biosimilar development and competitive pricing strategies.
-
Demand growth is contingent on expanded indications and emerging resistance to initial treatment lines.
-
Reimbursement policies in the U.S. and Europe will heavily influence actual market penetration and drug pricing.
Summary
Rucaparib's market is mature within ovarian cancer, with sales expected to plateau or decline slightly due to biosimilar threats and competitive pressures. Price reduction trajectories are modest; however, upcoming indications could sustain revenue growth. Industry consolidation and policies promoting biosimilar adoption could accelerate price decreases after patent expiration.
Key Takeaways
- Rucaparib (NDC 70677-1076) is a significant player within PARP inhibitor therapy, with stable demand in ovarian cancer.
- Market growth is constrained by competition and biosimilar development, though pipeline expansions could open new avenues.
- Prices are projected to decline gradually over the next five years, primarily due to biosimilar emergence.
- Revenue is sensitive to payer policies, patent protections, and clinical trial results expanding indications.
- Competitive landscape favors Olaparib due to broader indications and higher market share, but Rucaparib maintains a notable position in niche segments.
FAQs
1. What is the current price of Rucaparib?
The wholesale acquisition cost (WAC) is approximately $11,000 per month as of 2023.
2. How does Rucaparib compare with competitors?
It has lower sales than Olaparib but remains competitive in ovarian cancer. Pricing per month is similar, with slight variations.
3. What is the potential impact of biosimilars on Rucaparib?
Biosimilars are expected to enter the market post-patent expiry around 2031, potentially reducing prices by 20-40%.
4. Are there upcoming indications that could expand Rucaparib’s market?
Yes, ongoing trials in prostate, breast, and pancreatic cancers could broaden its application and sales.
5. What are the main drivers of future price trends?
Patent expiry, biosimilar competition, reimbursement policies, and clinical efficacy data will influence pricing.
References
[1] IQVIA, Prescription Data, 2022
[2] Medi-Span, Price Data, 2023
